Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials

Manish R. Sharma, Elizabeth Gray, Richard M. Goldberg, Daniel J. Sargent, Theodore G. Karrison

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: The optimal end point for randomized phase II trials of anticancer therapies remains controversial We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]) Methods: Tumor measurements and progression-free survival (PFS) data were obtained for 1,471 patients; 1,002 had consistently measured tumors and were resampled (5,000 replicates) to simulate two-arm, randomized phase II trials with α = 0.10 (one sided) and 20 to 80 patients per arm. End points included log ratio of tumor size at 6, 12, and 18 weeks relative to baseline; time to tumor growth (TTG), estimated using a nonlinear mixed-effects model; and PFS. Arms were compared using rank sum tests for log ratio and TTG and a log-rank test for PFS Results: For FOLFOX versus IFL, TTG and PFS had similar power, with both exceeding the power of log ratio at 18 weeks; for FOLFOX versus IROX, TTG and log ratio at 18 weeks had similar power, with both exceeding the power of PFS. The best end points exhibited > 80% power with 60 to 80 patients per arm Conclusion: TTG is a powerful end point for randomized phase II trials of cytotoxic therapies in metastatic colorectal cancer; it was either comparable or superior to PFS and log ratio at 18 weeks. Additional studies will be needed to clarify the potential of TTG as a phase II end point.

Original languageEnglish (US)
Pages (from-to)36-41
Number of pages6
JournalJournal of Clinical Oncology
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

oxaliplatin
irinotecan
Disease-Free Survival
Neoplasms
Growth
Leucovorin
Fluorouracil
Colorectal Neoplasms
Nonparametric Statistics
Therapeutics
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. / Sharma, Manish R.; Gray, Elizabeth; Goldberg, Richard M.; Sargent, Daniel J.; Karrison, Theodore G.

In: Journal of Clinical Oncology, Vol. 33, No. 1, 01.01.2015, p. 36-41.

Research output: Contribution to journalArticle

Sharma, Manish R. ; Gray, Elizabeth ; Goldberg, Richard M. ; Sargent, Daniel J. ; Karrison, Theodore G. / Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 1. pp. 36-41.
@article{8ddd6c816883405aaf656da678731767,
title = "Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials",
abstract = "Purpose: The optimal end point for randomized phase II trials of anticancer therapies remains controversial We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]) Methods: Tumor measurements and progression-free survival (PFS) data were obtained for 1,471 patients; 1,002 had consistently measured tumors and were resampled (5,000 replicates) to simulate two-arm, randomized phase II trials with α = 0.10 (one sided) and 20 to 80 patients per arm. End points included log ratio of tumor size at 6, 12, and 18 weeks relative to baseline; time to tumor growth (TTG), estimated using a nonlinear mixed-effects model; and PFS. Arms were compared using rank sum tests for log ratio and TTG and a log-rank test for PFS Results: For FOLFOX versus IFL, TTG and PFS had similar power, with both exceeding the power of log ratio at 18 weeks; for FOLFOX versus IROX, TTG and log ratio at 18 weeks had similar power, with both exceeding the power of PFS. The best end points exhibited > 80{\%} power with 60 to 80 patients per arm Conclusion: TTG is a powerful end point for randomized phase II trials of cytotoxic therapies in metastatic colorectal cancer; it was either comparable or superior to PFS and log ratio at 18 weeks. Additional studies will be needed to clarify the potential of TTG as a phase II end point.",
author = "Sharma, {Manish R.} and Elizabeth Gray and Goldberg, {Richard M.} and Sargent, {Daniel J.} and Karrison, {Theodore G.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1200/JCO.2014.57.2826",
language = "English (US)",
volume = "33",
pages = "36--41",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials

AU - Sharma, Manish R.

AU - Gray, Elizabeth

AU - Goldberg, Richard M.

AU - Sargent, Daniel J.

AU - Karrison, Theodore G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: The optimal end point for randomized phase II trials of anticancer therapies remains controversial We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]) Methods: Tumor measurements and progression-free survival (PFS) data were obtained for 1,471 patients; 1,002 had consistently measured tumors and were resampled (5,000 replicates) to simulate two-arm, randomized phase II trials with α = 0.10 (one sided) and 20 to 80 patients per arm. End points included log ratio of tumor size at 6, 12, and 18 weeks relative to baseline; time to tumor growth (TTG), estimated using a nonlinear mixed-effects model; and PFS. Arms were compared using rank sum tests for log ratio and TTG and a log-rank test for PFS Results: For FOLFOX versus IFL, TTG and PFS had similar power, with both exceeding the power of log ratio at 18 weeks; for FOLFOX versus IROX, TTG and log ratio at 18 weeks had similar power, with both exceeding the power of PFS. The best end points exhibited > 80% power with 60 to 80 patients per arm Conclusion: TTG is a powerful end point for randomized phase II trials of cytotoxic therapies in metastatic colorectal cancer; it was either comparable or superior to PFS and log ratio at 18 weeks. Additional studies will be needed to clarify the potential of TTG as a phase II end point.

AB - Purpose: The optimal end point for randomized phase II trials of anticancer therapies remains controversial We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]) Methods: Tumor measurements and progression-free survival (PFS) data were obtained for 1,471 patients; 1,002 had consistently measured tumors and were resampled (5,000 replicates) to simulate two-arm, randomized phase II trials with α = 0.10 (one sided) and 20 to 80 patients per arm. End points included log ratio of tumor size at 6, 12, and 18 weeks relative to baseline; time to tumor growth (TTG), estimated using a nonlinear mixed-effects model; and PFS. Arms were compared using rank sum tests for log ratio and TTG and a log-rank test for PFS Results: For FOLFOX versus IFL, TTG and PFS had similar power, with both exceeding the power of log ratio at 18 weeks; for FOLFOX versus IROX, TTG and log ratio at 18 weeks had similar power, with both exceeding the power of PFS. The best end points exhibited > 80% power with 60 to 80 patients per arm Conclusion: TTG is a powerful end point for randomized phase II trials of cytotoxic therapies in metastatic colorectal cancer; it was either comparable or superior to PFS and log ratio at 18 weeks. Additional studies will be needed to clarify the potential of TTG as a phase II end point.

UR - http://www.scopus.com/inward/record.url?scp=84920612560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920612560&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.57.2826

DO - 10.1200/JCO.2014.57.2826

M3 - Article

C2 - 25349295

AN - SCOPUS:84920612560

VL - 33

SP - 36

EP - 41

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -